|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||35.93 / 75.36|
Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today announced that it is discontinuing the phase 3 CASCADE clinical trial of vadastuximab talirine (SGN-CD33A) in frontline older acute myeloid...
Seattle Genetics, Inc. (Nasdaq: SGEN) and Bristol-Myers Squibb Company (NYSE: BMY) today highlighted an updated interim analysis from the ongoing phase 1/2 clinical trial evaluating ADCETRIS (brentuximab vedotin)...
Huge profits could be on the doorstep for these hot breakout setups.
Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc.
Seattle Genetics, Inc. (NASDAQ: SGEN) and Astellas today highlighted updated phase 1 data for enfortumab vedotin (ASG-22ME) studied as monotherapy treatment for metastatic urothelial cancer (mUC) in an oral...
-Pivotal Monotherapy Phase 2 Trial Initiation Planned for 2017-
Bristol-Myers Squibb Company (NYSE:BMY) and Seattle Genetics, Inc.
Here are Tuesday's top research calls, including downgrades for Cisco Systems and TherapeuticsMD, and new coverage of Costco and J.C. Penney.
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Bank of America Merrill Lynch 2017 Healthcare Conference on Tuesday, May 16 at 9:20 a.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AOSL, AVD, BCC, BGSF, CDR, CTRE, DV, LUK, PHX, PRLB, RTIX, SFM, STAY, TRP, WAGE, ZAGG Downgrades: ABCO, ACIW, AMAG, CQP, HDNG, INT, NEWM, RGS, SGEN, SSP, TAC Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
Delaware Vice Chancellor J. Travis Laster in March halted the deal as a result of a lawsuit filed by VenBio Partners, an activist firm invested in Immunomedics.
Immunomedics and Seattle Genetics have agreed to terminate the license pact that was first announced in February.
Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today announced that it has agreed to terminate its license agreement with Immunomedics, Inc.
Seattle Genetics, Inc. (NASDAQ: SGEN), a global biotechnology company, today reported financial results for the first quarter ended March 31, 2017.
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its first quarter financial results on Thursday, April 27, 2017, after the close of financial markets.
Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today highlighted multiple data presentations that support the company's advancing antibody-drug conjugate (ADC) and immuno-oncology programs at...
Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today announced its broad presence at the upcoming 108 th Annual Meeting of the American Association for Cancer Research (AACR) being held April...
Jim Cramer says it's his job to educate and entertain you, as well as help you make and save money.
Jim Cramer is bullish on Cisco Systems, Check Point Software and CyberArk Software.
The biotech company embattled by activist investor VenBio may not be able to go through with its licensing deal.
Seattle Genetics, Inc. (Nasdaq:SGEN), a global biotechnology company, today announced that the U.
The newly reconstituted Immunomedics board is likely to start a search for a new CEO and could either renegotiate the IMMU-132 deal with Seattle Genetics or cancel it.
Annual Meeting to Proceed as Scheduled at 10 a.m. ET Today
The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Seattle Genetics Inc.
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the following upcoming investor conferences.
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Western District of Washington on behalf of investors who purchased Seattle Genetics Inc.